Literature DB >> 9122515

Body mass index and mortality in patients with severe alpha 1-antitrypsin deficiency.

N Seersholm1.   

Abstract

It appears that patients with advanced stages of chronic obstructive pulmonary disease, and particularly emphysema, lose weight and have higher mortality even after controlling for lung function. In the present study, mortality of alpha 1-antitrypsin-deficiency patients PiZ as a function of body mass index (BMI) with control for FEV1, sex and smoking habits was studied. A total of 342 patients participated with a mean follow-up time of 7.6 yr. Ninety patients had BMI under 20 kg m-2, which was the cut-off defining underweight patients. The patients were divided into three groups according to their initial FEV1 % predicted: < 30%, 30-64% and > or = 65%. The underweight patients had significantly higher mortality in the two groups with the lowest FEV1 % predicted. A Cox regression model was applied to control for potential confounders. The risk ratio for the underweight patients was 1.6 (P = 0.03) after controlling for FEV1, age, sex and smoking habits. It is concluded that low body weight is an independent predictor of mortality, but the reason is still unclear.

Entities:  

Mesh:

Year:  1997        PMID: 9122515     DOI: 10.1016/s0954-6111(97)90071-8

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  4 in total

1.  Predictors of mortality in alpha1-antitrypsin deficiency.

Authors:  P A Dawkins; L J Dowson; P J Guest; R A Stockley
Journal:  Thorax       Date:  2003-12       Impact factor: 9.139

2.  Body mass index and mortality in chronic obstructive pulmonary disease: a meta-analysis.

Authors:  Chao Cao; Ran Wang; Jianmiao Wang; Hansvin Bunjhoo; Yongjian Xu; Weining Xiong
Journal:  PLoS One       Date:  2012-08-24       Impact factor: 3.240

Review 3.  Update on α1-antitrypsin deficiency.

Authors:  Ilaria Ferrarotti; Stefania Ottaviani; Annalisa De Silvestri; Angelo G Corsico
Journal:  Breathe (Sheff)       Date:  2018-06

Review 4.  Augmentation therapy for alpha-1 antitrypsin deficiency: towards a personalised approach.

Authors:  Robert A Stockley; Marc Miravitlles; Claus Vogelmeier
Journal:  Orphanet J Rare Dis       Date:  2013-09-24       Impact factor: 4.123

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.